SPECIAL REPORT - Excited About Excipients?
Kurt R. Sedo and Cindy H. Dubin take a deep dive into the excipient market, highlighting how new excipients enable advanced drug products and how AI and computation tools are helping match excipients to APIs.
FORMULATION FORUM - Oral Delivery of Nanocrystal Suspensions
Dr. Shaukat Ali and Dr. Jim Huang shed light on the challenges and opportunities to improve solubility and enhance oral bioavailability of molecules in nanocrystals or crystalline suspensions.
DRUG DELIVERY - Powder to Patient: Advancing Reconstitutable Injectables Through Integrated Aseptic Powder Filling & Next-Generation Dual Chamber Delivery
Laxman Halleppanavar and David Phasey offer a focused perspective on connecting formulation, particle engineering, aseptic manufacturing, device design, and patient use within one scalable development pathway.
SILICONE CHEMISTRY - Modification of Silicone Chemistry & Its Influence on Release Rates of APIs
Matthew Kihara explains how silicone lends itself to optimization, customization, and therapeutic performance, and that modifying silicone chemistry presents an opportunity to optimize drug release behavior and system performance.
VACCINE TECHNOLOGY - Delivering Better Global Vaccination Programs by Removing the Needle, Syringe & Fridge
Robin Cohen says that novel vaccine technology does not relate simply to the antigen, but also to method of administration and route of delivery, stressing that removing needle, syringe, and refrigerator are a step toward better vaccination programs.
SPECIAL FEATURE - Excipients: Strategic Enablers of Innovation
Ahead of CPHI, Cindy H. Dubin learns from leading excipient suppliers how multi-functional and organic excipients are impacting novel formulations and how AI is becoming a valuable tool in formulation development.
EXECUTIVE INTERVIEW - Lonza: From Formulation to Scale-Up: Advancing Dry Powder Inhalation for Biologics
Dr. Kim Shepard and Dr. Beatriz Fernandes talk about the evolving respiratory delivery landscape, the technologies shaping the field, and development strategies for addressing formulation while initiating risk mitigation.
CONTROLLED RELEASE - Alginate Beads for Oral Drug Delivery: Formulation Strategies for Controlled Release & Enhanced Bioavailability
Vardan Ter-Antonyan, Casey Kikendall, and John Davis review the formulation principles governing calcium alginate bead performance and discuss the relationship between bead structure and controlled release.
ARTIFICIAL INTELLIGENCE - AI Has Transformed the Pharmacovigilence Landscape
Raj More surveys the field of AI tools and looks at some emerging trends as well as factors that will influence the development of these platforms.
EXECUTIVE INTERVIEW - Bone Biologics Corp.: Recombinant Protein Development in Engineering Active Orthobiologics & Targeted Bone Therapies
Jeffrey Frelick describes how Bone Biologics’ lead proprietary recombinant human protein is addressing the challenge of balancing strong bone growth with patient safety.
LIFE SCIENCE PERSPECTIVE - A Validated Modality Changes the Equation
Kelly Page shares her personal perspective on taking therapeutic modalities across the finish line and how she applies what she learns into future programs to turn scientific progress into improved patient outcomes.
SPECIAL FEATURE - Injection Devices: Advancements Converge to Expand Patient Possibilities
Cindy H. Dubin speaks with injection device developers about creating devices that are intelligent, intuitive, patient-centric systems that make advanced therapies easier, safer, and more accessible to use at home.
ARTIFICIAL INTELLIGENCE - AI/ML Supporting Biomarker & Target Discovery
William Whitford explains how Artificial Intelligence/Machine Learning provide new capabilities in analyzing the rapidly increasing type and amount of biological data employed in identifying potential biomarker and disease targets.
EXECUTIVE INTERVIEW - Portal Instruments: Beyond Springs – Portal Prime Nexus™ Autoinjector is a Versatile Solution for Biologics
As biologics become larger, more viscous, and more complex, software offers a fundamentally better way to control and optimize delivery.
PLATFORM TECHNOLOGY - How a Novel Immunotherapy Platform is Unlocking the Cancer-Fighting Potential of Unconventional T Cells
Michal Sheleg, PhD, shines a spotlight on the promise of MAIT cells to fight cancer by turning to an untapped source: human placentas.
Expert Insights Videos
Go beyond the written word with our new podcast series, featuring in-depth conversations with industry leaders shaping the future of drug development and delivery. Each episode explores real-world challenges, emerging technologies, and the insights driving innovation across the pharmaceutical landscape.
Oral Peptide Drug Delivery: Overcoming Bioavailability & Formulation Challenges
The pharmaceutical industry is increasingly exploring oral delivery as an alternative to injections for peptides, proteins, oligonucleotides, and other complex molecules—but significant formulation and biological…
The Future of Injection Devices: Key Trends Shaping Drug Delivery
Injection devices continue to evolve as pharmaceutical companies look for more effective, convenient, and patient-focused ways to deliver increasingly complex therapies.
EXPERT CONTENT & RESOURCES
Whether you're a researcher, a pharmaceutical professional, or simply interested in the latest advancements in drug development and delivery technology, you'll find a wealth of insightful expertise and current resources here.
Monoclonal vs Polyclonal Antibody Production
Antibody-based therapeutics have reshaped modern medicine. With demand soaring, choosing the appropriate production path can save months and millions.
Case study: Modeling polymor interactions to improve amorphous dispersion design
In this case study, OSDPredict™ narrowed formulation options early, focusing development on the most viable strategies which reduced experimental burden and conserved valuable materials.
The Last Mile of Digital Implementation: A Technical Framework for Turning Clinical Technology Adoption Into Measurable Value
As clinical trials become increasingly digitally enabled, organizations must look beyond successful technology deployment to determine whether new tools are delivering measurable value. This article presents a five-layer framework for evaluating technical fitness, workflow integration, adoption, data reliability, and operational outcomes to help translate clinical technology investments into better trial execution and evidence.
FROM ASSESSMENT TO SUSTAINABLE ACTION - Circular Economy Strategies & Practical Routes to Lower-Impact Medical Devices
AstraZeneca and Novo Nordisk have both committed to science-based net-zero across their full value chains by 2045. However, decarbonizing manufacturing alone leaves most of the footprint untouched. Meeting these net-zero targets requires changes to the products themselves, the devices that deliver them, and the systems built around them, including the reprocessing and reuse networks. The route to a more sustainable device is not the same for every product, and the single biggest determinant of what is achievable is where a device sits in its product development lifecycle when sustainability is first considered.
Managing Fragmented Small-Molecule Supply Chains Through Strategic Secondary Bulk Packaging
As small-molecule manufacturing becomes increasingly fragmented across regions, specialist facilities, and CDMOs, every product handoff introduces new opportunities for delay and variability. A strategic bulk secondary packaging approach can help standardize product handling, improve operational control, and strengthen resilience across complex pharmaceutical supply chains.
Have expert content to share? Contact us
WHITEPAPERS & WEBINARS
WHITEPAPER - Large-Scale LNP Process Conversions
Large-Scale LNP Process Conversions: The many hurdles of LNP scale-up and what to consider Lipid nanoparticle (LNP) formulation development begins on a small scale, often…
WEBINAR - Challenges of Sustained Release Drug Delivery Devices
Sustained release drug delivery is rapidly expanding across respiratory, ophthalmic, transdermal, and implantable applications, but translating products from development to manufacturing remains both complex and…
WHITEPAPER - Streamlined Product Development Leveraging Pharmaceutical Classification Models
A technology agnostic approach based on a fundamental understanding of API properties, a well-defined yet flexible target product profile, and a mindset for scalability and…
WEBINAR ON DEMAND - Heat Without Harm: The Reality of Hot Melt Extrusion Webinar
In a 2025 industry survey (1), 76% of respondents selected ‘risk of thermal degradation’ as a source of hesitation to pursue hot melt extrusion (HME). Concerns about heat-sensitive APIs frequently lead development teams to rule out HME early — often before conducting a thorough scientific evaluation of their formulation options.
But thermal risk is frequently overstated. In this on-demand webinar, Stefanie Hauck, Senior Director PDS&T Pharm. Tech. at AbbVie Contract Manufacturing, explains why many compounds initially considered unsuitable for HME can be successfully processed with the right expertise.
WHITEPAPER - Container Closure Integrity Issues in Cell & Gene Therapy Products
The cell and gene therapy (CGT) product market is expected to grow at a very high rate of around 20-30% per year over the next 10 years. Increasing number of approvals, expansion of target diseases, accelerated investment and innovation, and advent of aging population are the key factors for the growth.
WEBINAR ON DEMAND: Why early matters: Data-driven strategies to de-risk OSD development
This on-demand webinar focuses on how data-driven characterization, predictive modeling, and Quality by Design (QbD) approaches help teams identify and address risks earlier—when decisions are more flexible and impacts easier to manage, before scale-up begins.
eBook - An Introduction to PLG Polymers for Long‑Acting Drug Delivery
Bioabsorbable poly(lactide-co‑glycolide) (PLG) polymers and poly(lactic acid-co-glycolic acid) (PLGA) have become an essential part of modern healthcare. Over the past five decades, these polymers have…
WHITEPAPER - From Service Provider to Strategic Partner
As drug development grows more complex and timelines compress, sponsors require CDMO relationships built on integration, flexibility, and shared accountability.
MARKET NEWS & TRENDS
Thermo Fisher Expands Drug Development and Manufacturing Offerings at CPHI Milan 2026
Thermo Fisher Scientific is using CPHI Milan 2026 to highlight a broader set of drug development, manufacturing, clinical supply, and digital capabilities aimed at helping…
Terumo Launches K-Pack Embrace Safety Needle for Automated Drug Co-packing
Terumo Corp. has launched a new active safety needle designed to support automated processes used to combine injection needles with drug products and syringes. The…
PacBio, TychoBio Join Forces to Build AI Models for Rare Disease RNA Therapies
PacBio and AI drug discovery company TychoBio are collaborating on a large-scale sequencing effort aimed at improving the design of RNA-based treatments for rare diseases.…
Biopharma Industry Launches Consortium to Build Digital Standards for CMC
A new industry consortium launched today aims to tackle one of biopharma's persistent digitalization challenges: bringing chemistry, manufacturing and controls (CMC) processes into a standardized,…
CPHI Broadens European Strategy With New Spain Event and Specialist Frankfurt Zones
CPHI is expanding its European event portfolio in 2027, adding a new country-focused pharmaceutical exhibition in Spain while expanding its flagship Frankfurt event into several…
Upperton Unveils New Brand as it Expands Specialist CDMO Offering
Nottingham, UK-based pharmaceutical development and manufacturing company Upperton Pharma Solutions has introduced a new brand identity as it enters a new stage of growth, positioning…
Ofichem to Acquire Kinentia Biosciences, Expanding US Drug Substance Footprint
Ofichem is set to establish its first operational presence in the US drug substance market through an agreement to acquire New York-based CDMO Kinentia Biosciences.…
SGD Pharma Broadens Glass Vial Portfolio With New Nasal and RTU Offerings
SGD Pharma is expanding its pharmaceutical glass packaging portfolio with new molded and tubular vial solutions aimed at drug developers working with high-value and increasingly…
CPHI Milan Brings Pharma Industry Together for Practical Sustainability Summit
Pharmaceutical companies, suppliers and sustainability specialists will gather in Milan at CPHI this week for a new industry forum aimed at moving sustainability discussions from…
Agilent Adds Boulder Lab to Expand Oligonucleotide Manufacturing Capabilities
Agilent Technologies is expanding its oligonucleotide manufacturing infrastructure with a new laboratory in Boulder, Colorado, aimed at advancing and scaling emerging production technologies for oligonucleotide…
Credence MedSystems Earns ISO 13485 Certification as it Expands Drug Delivery Manufacturing Readiness
Credence MedSystems has secured ISO 13485:2016 certification for its quality management system, a milestone the drug-delivery technology company says strengthens its position as a potential…
Novartis Pays $575M Upfront for Abogen's mRNA T-Cell Engager
Novartis has agreed to pay Abogen Biosciences $575 million upfront for worldwide rights to an experimental mRNA-encoded T-cell engager, in a deal that could reach…
Lifecore Biomedical to Be Acquired by Webster Equity Partners in Deal Valued at Up to $663.7M
Lifecore Biomedical has agreed to be acquired by private equity firm Webster Equity Partners in a transaction that could be worth as much as $663.7…
Lonza and Asimov Team Up to Tackle In Vivo Lentiviral Manufacturing Challenges
Lonza and Asimov have entered into a strategic collaboration focused on developing scalable manufacturing approaches for lentiviral vectors (LVVs) intended for emerging in vivo applications.…
Adare Partners With OnDosis on Precision-Dosing Platform for ADHD Treatment
OnDosis and Adare Pharma Solutions have entered into a strategic collaboration aimed at advancing OnDosis' lead U.S. drug-development program for attention-deficit/hyperactivity disorder (ADHD). Under the…
Johnson & Johnson Reports Two-Year Icotrokinra Data in High-Impact Plaque Psoriasis
Johnson & Johnson has reported two-year results from the Phase 3 ICONIC-TOTAL study showing sustained improvements in skin clearance among adults and adolescents with plaque…
Lonza Expands Aseptic Spray Drying Platform for High-Dose Biologics
Lonza is expanding development of an aseptic spray drying platform designed to address some of the formulation and delivery challenges associated with highly concentrated biologic…
Ensera Launches Alliance Network to Support Combination-Product Commercialization
Ensera has launched a new alliance network designed to help pharmaceutical companies navigate the commercialization of injectable drug-device combination products. The Ensera Alliance Network brings…
Gattefossé Adds Vitamin E TPGS and Solid Surfactants to Oral Drug Delivery Portfolio
Gattefossé is expanding its pharmaceutical excipient portfolio with the commercial launch of Vitamin E TPGS and the introduction of a new range of solid surfactants…
ESTEVE CDMO Commits Additional $17.5M to Expand U.S. Manufacturing Capacity
ESTEVE CDMO is expanding its manufacturing and development capabilities in the United States with a further $17.5 million investment at its Morton Grove, Illinois facility.…
